The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers.

One of the most effective ways to reduce overtreatment of prostate cancer is to limit its detection in men with low-risk disease. Although many data are currently missing, we foresee a future with reduced prostate-specific antigen (PSA) testing in men selected through baseline PSA values or genetic predisposition.

Then selective biopsy using multiparametric magnetic resonance imaging and longitudinal biomarkers will play a role.

European urology. 2016 Feb 22 [Epub ahead of print]

Giorgio Gandaglia, Alberto Briganti, Nicola Fossati, Andrea Salonia, Alexandre Mottrie, James Catto, Francesco Montorsi

Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy; OLV Vattikuti Robotic Surgery Institute, Melle, Belgium., Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy., Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy., Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy., OLV Vattikuti Robotic Surgery Institute, Melle, Belgium., Academic Urology Unit and Institute for Cancer Studies, The Medical School, University of Sheffield, Sheffield, UK., Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy.  

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe